NASDAQ: BDTXBlack Diamond Therapeutics Inc Stock
$1.71+0.01 (+0.59%)
Updated Jun 26, 2026
BDTX Price
$1.71
Fair Value Price
N/A
Market Cap
$97.99M
52 Week Low
$1.60
52 Week High
$4.94
P/E
-2.22x
P/B
0.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$43.21M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.27
Operating Cash Flow
-$34M
Beta
1.66
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BDTX Overview
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BDTX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important BDTX news, forecast changes, insider trades & much more!
BDTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BDTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BDTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BDTX is good value based on its book value relative to its share price (0.94x), compared to the US Biotechnology industry average (5.34x)
P/B vs Industry Valuation
BDTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BDTX due diligence checks available for Premium users.
Valuation
BDTX fair value
Fair Value of BDTX stock based on Discounted Cash Flow (DCF)
Price
$1.71
Fair Value
$6.35
Undervalued by
73.09%
BDTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BDTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.22x
Industry
16.27x
Market
12.39x
BDTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.94x
Industry
5.34x
BDTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BDTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.0M
Profit Margin
0%
BDTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$132.9M
Liabilities
$28.6M
Debt to equity
0.27
BDTX's short-term assets ($122.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BDTX's short-term assets ($122.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BDTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BDTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.2M
Investing
$19.5M
Financing
-$185.0k
BDTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BDTX vs Biotech Stocks
Black Diamond Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.